SOURCE: Altair Nanotechnologies, Inc.

August 12, 2005 07:30 ET

Altair Nanotechnologies Provides Product Updates

RENO, NV -- (MARKET WIRE) -- August 12, 2005 -- Altair Nanotechnologies Inc. (NASDAQ: ALTI), provided product updates in preparation for its financial conference call scheduled for today. Management provides product updates so shareholders and potential investors have an opportunity to review product information and status of Altairnano's progress in commercializing its product technology prior to the conference call.

Altairnano management is hosting its Second Quarter Financial Results conference call, Friday, August 12 at 11:00 AM Eastern Daylight Time. The dial-in number is 973 935 2981. Additionally, the conference call is being webcast by ViaVid Communications and can be accessed by visiting
http://viavid.net/dce.aspx?sid=000027D6 or Altair's web site, www.altairnano.com.

Product Updates

The following product updates highlight products that are in the stage of market entry where Altairnano is engaging with commercial partners. In each segment Altairnano is focused on building high-growth, long-term relationships with companies that Altairnano assesses as the major market suppliers for the purpose of creating sustainable revenue growth. During the conference call, Altairnano management will provide a question & answer session to address questions about Altairnano's technologies, products, market applications and finances.

--  Altairnano's RenaZorb, a phosphate binding drug candidate for humans,
    was licensed to Spectrum Pharmaceuticals.   Additional animal testing of
    the RenaZorb™ product was completed and analytical testing of the blood
    and urine samples has begun, which is expected to be completed in September
    2005.   Concurrently, Altair and Spectrum are continuing with their
    development work to prepare for a pre-IND meeting with the FDA.
    
--  The licensing of Renalan (similar chemistry to RenaZorb) as a
    potential drug for treatment of excess phosphate in dogs and cats with
    chronic renal failure is progressing with early-stage commercial
    discussions with potential partners.   Altairnano estimates that the
    potential market for phosphate limiting drugs for animals is estimated in
    excess of $100 million per year.
    
--  Altairnano continues with field trials and market introduction of
    NanoCheck™ making its first commercial shipment of NanoCheck during the
    quarter ended June 30. This shipment is being used by potential licensees
    or purchasers of NanoCheck for the current project phase, the summer field
    trials program, where NanoCheck is performing according to Altair's
    expectations in a significant number of consumer pools.    In preparation
    for an anticipated fourth quarter product launch, Altairnano is in contract
    negotiations with pool chemical companies that are major suppliers to the
    recreational water market of more than 10 million pools.
    
--  Altairnano is shipping advanced electrode battery nanomaterials to its
    development partner, Advanced Battery Technologies and is shipping
    development samples to other lithium ion battery manufacturers in North
    America, Europe and Asia.  Advanced Battery's Phase 1 - Product Research
    has completed testing of batteries utilizing Altairnano's battery
    electrode, which provided significantly improved recharging capability over
    traditional battery materials.   Additionally, Altairnano announced that it
    had received an order from Advanced Battery for 2,200 pounds (one metric
    ton) of Altairnano anode electrode nanomaterials for Phase 2 - Product
    Development.   These materials are intended to be used to construct
    developmental polymer lithium ion batteries designed to power one electric
    bus and one electric sedan. Additional information on Altairnano's battery
    materials program is provided in a separate release dated August 12, 2005.
    
--  Altairnano received a Phase ll grant of $476,850 from the National
    Science Foundation to develop battery cathode electrode nanomaterials to
    provide matched anode-cathode electrode materials for optimizing the
    electrochemical performance of lithium ion batteries.   These materials
    will form the basis for a second generation of battery electrode
    nanomaterials.
    
--  Altairnano has entered into an agreement with Western Oil Sands to
    provide pilot plant and office space within Altairnano's facilities for
    five employees and consultants of Western Oil Sands' to facilitate on-site
    collaboration between the two companies in furthering the engineering study
    of manufacturing TiO2 pigment from Western's tar sand tailings using
    Altairnano's AHP process.
    

ABOUT ALTAIR NANOTECHNOLOGIES INC.

Altairnano is a leading supplier and innovator of advanced ceramic nanomaterial technology. Based in Reno, Nevada, Altairnano has assembled a unique team of materials scientists who, coupled in collaborative ventures with industry partners and leading academic centers, have pioneered an array of intellectual property and products.

Altairnano's robust proprietary technology platforms produce a variety of crystalline and non-crystalline nanomaterials of unique structure, performance, quality and cost. The company has scalable manufacturing capability to meet emerging nanomaterials demands, with the production capacity of hundreds of tons of nanomaterials.

Altairnano's two divisions, Life Sciences and Performance Materials, are focused on applications where its nanotechnology may enable new high growth markets. The Life Sciences Division is pursuing market applications in pharmaceuticals, drug delivery, dental materials and other medical markets. The Performance Materials Division is focused on market applications in advanced materials for paints and coatings; air and water treatment and alternative energy including new Li Ion battery electrode materials. For additional information on Altairnano and its nanomaterials, visit www.altairnano.com

Altairnano™, Altair Nanotechnologies Inc.®, RenaZorb™, NanoCheck™, TiNano Spheres™ and the Hydrochloride Pigment Process™ are trademarks or registered trademarks of Altair Nanotechnologies Inc.

Forward-Looking Statements

This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, may involve risks, uncertainties and other factors that may cause the company's actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, the risks that Altairnano's numerous development stage products will not be developed to the point of commercialization or that, even if commercialized, no market will exist for such products or Altairnano will fail to effectively market to customers in a market; that products subject to existing license agreements, including Altairnano's pigment process (AHPP) and RenaZorb, will not be commercially developed and, even if developed, will not generate significant royalty payments; and that Altairnano will not be able to enter into license or productions agreements with respect to TiNano Sphere, Nanocheck, Renalan, its battery electrode materials or other products that Altairnano expects industry partners to develop and market. In particularly, the projected year-end market introduction of products containing Nanocheck is not within the control of Altairnano and could be canceled or delayed for various reasons, including if current testing does not reveal positive results, Altair is unable to enter into agreements with pool chemical distribution companies and/or product design, marketing and other deadlines are not met. In general, Altairnano is, and expects to be in the immediate future, dependent upon funds generated from sales of securities, grants, testing agreements, and licensing agreements to fund its testing, development and ongoing operations. In addition, other risks are identified in the company's most recent Annual Report on Form 10-K, as filed with the SEC. Such forward-looking statements speak only as of the date of this release. The company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in company expectations or results or any change in events.

Contact Information